What is MariTide (Maridebart Cafraglutide)?

Amgen's once-monthly antibody-peptide conjugate that blocks GIP receptors and activates GLP-1 receptors, in phase 3 obesity trials. News and evidence page only.

MariTide (Maridebart Cafraglutide) in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

30 registered trials · 2 indexed papers · 0 human / 5 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

MariTide is described as a GIP-receptor-blocking monoclonal antibody joined to two GLP-1 agonist peptides. The antibody gives it a long half-life, so it is dosed monthly (Véniant et al., 2024).

It is a large antibody conjugate made only by Amgen. There is no genuine research-vial supply, and anything sold under this name should be treated as unverified.

Mechanism (as described)

  • It combines GIP-receptor antagonism with GLP-1-receptor agonism, the opposite GIP approach to tirzepatide.

Evidence (as described)

  • The phase 3 MARITIME program in obesity, with and without type 2 diabetes, is ongoing.

Status

Investigational (phase 3). Not approved anywhere.

Registered human trials (30)

TrialPhaseStatusYearEnrolled
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesPhase 3not yet recruiting20261300
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightPhase 2active not recruiting2026180
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityPhase 1active not recruiting202649
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)Phase 3recruiting2026300
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)Phase 3recruiting2026950
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)Phase 3recruiting20263200
Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DosePhase 1not yet recruiting2026340
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightPhase 3not yet recruiting2026230
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightPhase 3active not recruiting20253853
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightPhase 3active not recruiting20251105
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseasePhase 3active not recruiting2025279
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityPhase 3recruiting202512800
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityPhase 3recruiting20255056
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusPhase 1active not recruiting202556
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyPhase 3active not recruiting2025250
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyPhase 3active not recruiting2025250
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsPhase 1completed2025348
Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityPhase 1completed202581
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsPhase 1completed2025349
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic FunctionPhase 1completed202536
The Effect of AMG 133 on Gastric EmptyingPhase 1completed202557
A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyPhase 1completed202544
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightPhase 1completed202420
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Phase 2active not recruiting2024409
A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityPhase 1completed2024120
A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityPhase 1completed202459
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityPhase 1completed2024154
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusPhase 2completed2023592
Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian ParticipantsPhase 1completed202134
Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityPhase 1completed2020110

Peer-reviewed studies (2)

PaperAuthorsJournalYearType
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 TrialJastreboff AM et al.The New England journal of medicine2025Randomized Controlled Trial
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settingsVéniant MM et al.Nature metabolism2024Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is MariTide (Maridebart Cafraglutide)?

Amgen's once-monthly antibody-peptide conjugate that blocks GIP receptors and activates GLP-1 receptors, in phase 3 obesity trials. News and evidence page only.

How many registered human trials study MariTide (Maridebart Cafraglutide)?

The PeptideWhiz trial index lists 30 registered trials for MariTide (Maridebart Cafraglutide), the most recent from 2026.

How much published research exists on MariTide (Maridebart Cafraglutide)?

The PeptideWhiz paper index links 2 PubMed papers to MariTide (Maridebart Cafraglutide); by study type, 0 human and 5 animal studies.

Which conditions is MariTide (Maridebart Cafraglutide) researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Fat loss, obesity & body recomposition, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Sleep apnea (obstructive), Sleep problems (incl. insomnia on peptides).

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).